Date: 2015-01-08
Type of information: R&D agreement
Compound: RabMAb® antibody pairs
Company: Abcam (UK) Institute of Molecular and Cell Biology (IMCB) (Singapore)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism:
Disease:
Details: * On January 8, 2015, Abcam, a global leader in the supply of life science research tools, announced it has signed a partnership agreement with the Institute of Molecular and Cell Biology (IMCB), a research institute under the Agency for Science, Technology and Research (A*STAR), Singapore. Under the terms of the agreement, Abcam will develop a range of RabMAb® antibody pairs against targets jointly selected by IMCB and Abcam, to be used by both organisations in the development of immunoassays for life scientists working in both research and in diagnostics.
Combining the biological research expertise at IMCB with Abcam’s RabMAb technology will enable rapid production of antibody pairs with a high level of affinity, specificity and validation. This will include antibody pairs to some of the most important targets in cytokine research, and to exciting novel proteins. The first antibody pairs are expected to be completed by August 2015 and available to the research market later in the year. This project represents the beginning of a planned multi-year collaboration between IMCB and Abcam.
Financial terms:
Latest news:
